Michael P Whyte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6585447/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hypophosphatasia: Vitamin B6 status of affected children and adults. Bone, 2022, 154, 116204.	1.4	9
2	Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 813-824.	1.8	36
3	Osteoprotegerin deficiency and aneurysm formation: Case report of iliac artery aneurysms in Juvenile Paget's disease. Annals of Vascular Surgery Brief Reports and Innovations, 2022, 2, 100065.	0.1	0
4	Periarticular calcifications containing giant pseudo-crystals of francolite in skeletal fluorosis from 1,1-difluoroethane â€`huffing― Bone, 2022, , 116421.	1.4	2
5	Skeletal and extraskeletal disorders of biomineralization. Nature Reviews Endocrinology, 2022, 18, 473-489.	4.3	25
6	Dysosteosclerosis: Clinical and Radiological Evolution Reflecting Genetic Heterogeneity. JBMR Plus, 2022, 6, .	1.3	2
7	Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. Bone, 2021, 142, 115664.	1.4	15
8	Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcified Tissue International, 2021, 108, 622-633.	1.5	26
9	Coalescing expansile skeletal disease: Delineation of an extraordinary osteopathy involving the IFITM5 mutation of osteogenesis imperfecta type V. Bone, 2021, 145, 115835.	1.4	7
10	Non-endemic skeletal fluorosis: Causes and associated secondary hyperparathyroidism (case report) Tj ETQq0 0 () rgBT /Ove	erlock 10 Tf :

11	Vitamin B6 deficiency with normal plasma levels of pyridoxal 5′-phosphate in perinatal hypophosphatasia. Bone, 2021, 150, 116007.	1.4	9
12	Adult hypophosphatasia treated with reduced frequency of teriparatide dosing. Journal of Musculoskeletal Neuronal Interactions, 2021, 21, 584-589.	0.1	1
13	Hypophosphatasia. , 2020, , 1569-1599.		3
14	Bruck syndrome 2 variant lacking congenital contractures and involving a novel compound heterozygous PLOD2 mutation. Bone, 2020, 130, 115047.	1.4	14
15	Xâ€Linked Hypophosphatemia: Uniquely Mild Disease Associated With <i>PHEX</i> 3′â€UTR Mutation c.*231A>G (A Retrospective Case–Control Study). Journal of Bone and Mineral Research, 2020, 35, 920-931.	3.1	12
16	Early-onset Paget's disease of bone in a Mexican family caused by a novel tandem duplication (77dup27) in TNFRSF11A that encodes RANK. Bone, 2020, 133, 115224.	1.4	7
17	Hypophosphatemic osteosclerosis, hyperostosis, and enthesopathy associated with novel homozygous mutations of DMP1 encoding dentin matrix protein 1 and SPP1 encoding osteopontin: The first digenic SIBLING protein osteopathy?. Bone, 2020, 132, 115190.	1.4	14
18	Growth Curves for Children with X-linked Hypophosphatemia. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3243-3249.	1.8	26

#	Article	IF	CITATIONS
19	High bone mass from mutation of low-density lipoprotein receptor-related protein 6 (LRP6). Bone, 2020, 141, 115550.	1.4	22
20	Persistent idiopathic hyperphosphatasemia from bone alkaline phosphatase in a healthy boy. Bone, 2020, 138, 115459.	1.4	4
21	The two faces of giant cell tumor of bone. Cancer Letters, 2020, 489, 1-8.	3.2	20
22	Genetics of Skeletal Disorders. Handbook of Experimental Pharmacology, 2020, 262, 325-351.	0.9	3
23	<i>ZNF687</i> Mutations in an Extended Cohort of Neoplastic Transformations in Paget's Disease of Bone: Implications for Clinical Pathology. Journal of Bone and Mineral Research, 2020, 35, 1974-1980.	3.1	9
24	Hyperphosphatemia with low FGF7 and normal FGF23 and sFRP4 levels in the circulation characterizes pediatric hypophosphatasia. Bone, 2020, 134, 115300.	1.4	10
25	Healing of vitamin D deficiency rickets complicating hypophosphatasia suggests a role beyond circulating mineral sufficiency for vitamin D in musculoskeletal health. Bone, 2020, 136, 115322.	1.4	12
26	Juvenile Paget's Disease From Heterozygous Mutation of SP7 Encoding Osterix (Specificity Protein 7,) Tj ETQq0	0 0 rgBT /	Overlock 107
27	Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody. Journal of Bone and Mineral Research, 2020, 36, 625-626.	3.1	2
28	SAT-384 Identification of Heterozygous LRP5 Mutation and a TGFβ-1 Variant of Unknown Significance in a Patient with Hearing Loss, High Bone Mass, and Oropharyngeal Exostoses. Journal of the Endocrine Society, 2020, 4, .	0.1	0
29	Skeletal fluorosis in a resettled refugee from Kakuma refugee camp. Lancet, The, 2019, 393, 223-225.	6.3	9
30	Absence of an osteopetrosis phenotype in IKBKG (NEMO) mutation-positive women: A case-control study. Bone, 2019, 121, 243-254.	1.4	4
31	New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6. Bone, 2019, 127, 228-243.	1.4	42
32	Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet, The, 2019, 393, 2416-2427.	6.3	229
33	No vascular calcification on cardiac computed tomography spanning asfotase alfa treatment for an elderly woman with hypophosphatasia. Bone, 2019, 122, 231-236.	1.4	11
34	Natural History of Perinatal and Infantile Hypophosphatasia: A Retrospective Study. Journal of Pediatrics, 2019, 209, 116-124.e4.	0.9	39
35	Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone, 2019, 121, 149-162.	1.4	99
36	Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm,	5.5	91

open-label, phase 2 extension trial. Lancet Diabetes and Endocrinology, the, 2019, 7, 93-105.

#	Article	IF	CITATIONS
37	Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 189-199.	5.5	115
38	Genetic approaches to metabolic bone diseases. British Journal of Clinical Pharmacology, 2019, 85, 1147-1160.	1.1	21
39	MON-516 Skeletal Fluorosis from Fluorocarbon Inhalation. Journal of the Endocrine Society, 2019, 3, .	0.1	0
40	OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH). Journal of the Endocrine Society, 2019, 3, .	0.1	0
41	Commentary. Clinical Chemistry, 2018, 64, 643-644.	1.5	1
42	Hypophosphatasia: Biochemical hallmarks validate the expanded pediatric clinical nosology. Bone, 2018, 110, 96-106.	1.4	36
43	Validation of a Novel Scoring System for Changes in Skeletal Manifestations of Hypophosphatasia in Newborns, Infants, and Children: The Radiographic Global Impression of Change Scale. Journal of Bone and Mineral Research, 2018, 33, 868-874.	3.1	33
44	Alkaline Phosphatase: Discovery and Naming of Our Favorite Enzyme. Journal of Bone and Mineral Research, 2018, 33, 362-364.	3.1	74
45	Gnathodiaphyseal dysplasia: Severe atypical presentation with novel heterozygous mutation of the anoctamin gene (ANO5). Bone, 2018, 107, 161-171.	1.4	23
46	Burosumab Therapy in Children with X-Linked Hypophosphatemia. New England Journal of Medicine, 2018, 378, 1987-1998.	13.9	339
47	Mendelian Disorders of RANKL/OPG/RANK/NF-κB Signaling. , 2018, , 453-468.		3
48	Hypophosphatasia and How Alkaline Phosphatase Promotes Mineralization. , 2018, , 481-505.		15
49	Heritable Renal Phosphate Wasting Disorders. , 2018, , 761-782.		1
50	Unique Variant of <i>NOD2</i> Pediatric Granulomatous Arthritis With Severe 1,25-Dihydroxyvitamin D-Mediated Hypercalcemia and Generalized Osteosclerosis. Journal of Bone and Mineral Research, 2018, 33, 2071-2080.	3.1	9
51	Approach to the Patient With Metabolic Bone Disease. , 2018, , 887-902.		1
52	Sclerosteosis: Report of type 1 or 2 in three Indian Tamil families and literature review. Bone, 2018, 116, 321-332.	1.4	17
53	Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges. Journal of Bone and Mineral Research, 2017, 32, 667-675.	3.1	110
54	Hypophosphatasia: An overview For 2017. Bone, 2017, 102, 15-25.	1.4	155

#	Article	IF	CITATIONS
55	Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS. Bone, 2017, 101, 145-155.	1.4	37
56	Skeletal Fluorosis Due To Inhalation Abuse of a Difluoroethane-Containing Computer Cleaner. Journal of Bone and Mineral Research, 2017, 32, 188-195.	3.1	25
57	Raine Syndrome (OMIM #259775), Caused By <i>FAM20C</i> Mutation, Is Congenital Sclerosing Osteomalacia With Cerebral Calcification (OMIM 259660). Journal of Bone and Mineral Research, 2017, 32, 757-769.	3.1	34
58	Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. Bone, 2017, 95, 151-161.	1.4	66
59	Idiopathic Acquired Osteosclerosis in a Middle-Aged Woman With Systemic Lupus Erythematosus. Journal of Bone and Mineral Research, 2016, 31, 1774-1782.	3.1	3
60	Auricular ossification: A newly recognized feature of osteoprotegerinâ€deficiency juvenile Paget disease. American Journal of Medical Genetics, Part A, 2016, 170, 978-985.	0.7	11
61	Adult Hypophosphatasia Treated with Teriparatide: Report of 2 Patients and Review of the Literature. Endocrine Practice, 2016, 22, 941-950.	1.1	47
62	Hypophosphatasia: Natural history study of 101 affected children investigated at one research center. Bone, 2016, 93, 125-138.	1.4	54
63	Commentary. Clinical Chemistry, 2016, 62, 688-688.	1.5	0
64	Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 334-342.	1.8	189
65	Alkaline Phosphatase and Hypophosphatasia. Calcified Tissue International, 2016, 98, 398-416.	1.5	280
66	Neonatal High Bone Mass With First Mutation of the NF-κB Complex: Heterozygous De Novo Missense (p.Asp512Ser) <i>RELA</i> (Rela/p65). Journal of Bone and Mineral Research, 2016, 31, 163-172.	3.1	21
67	Hypophosphatasia — aetiology, nosology, pathogenesis, diagnosis and treatment. Nature Reviews Endocrinology, 2016, 12, 233-246.	4.3	346
68	Congenital insensitivity to pain: Fracturing without apparent skeletal pathobiology caused by an autosomal dominant, second mutation in SCN11A encoding voltage-gated sodium channel 1.9. Bone, 2016, 84, 289-298.	1.4	58
69	Hereditary Disorders of the Skeleton. , 2016, , 1173-1183.e4.		2
70	Asfotase alfa therapy for children with hypophosphatasia. JCI Insight, 2016, 1, e85971.	2.3	123
71	Response to: A Rapid Skeletal Turnover in Radiographic Mimic of Osteopetrosis Might Be Secondary to Systemic Mastocytosis. Journal of Bone and Mineral Research, 2015, 30, 946-946.	3.1	1
72	Lenz-Majewski Hyperostotic Dwarfism with Hyperphosphoserinuria from a Novel Mutation in <i>PTDSS1</i> Encoding Phosphatidylserine Synthase 1. Journal of Bone and Mineral Research, 2015, 30, 606-614.	3.1	17

#	Article	IF	CITATIONS
73	<i>PHEX</i> 3′-UTR c.*231A>G Near The Polyadenylation Signal Is a Relatively Common, Mild, American Mutation That Masquerades as Sporadic or X-Linked Recessive Hypophosphatemic Rickets. Journal of Bone and Mineral Research, 2015, 30, 137-143.	3.1	20
74	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726.	9.4	310
75	Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype–phenotype correlations, codon bias and dominant-negative effects. Human Molecular Genetics, 2015, 24, 5079-5092.	1.4	69
76	Hypophosphatasia: Validation and expansion of the clinical nosology for children from 25years experience with 173 pediatric patients. Bone, 2015, 75, 229-239.	1.4	199
77	Juvenile Paget's disease with heterozygous duplication within TNFRSF11A encoding RANK. Bone, 2014, 68, 153-161.	1.4	42
78	Calcific Periarthritis as the Only Clinical Manifestation of Hypophosphatasia in Middle-Aged Sisters. Journal of Bone and Mineral Research, 2014, 29, 929-934.	3.1	64
79	Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 2014, 29, 1-23.	3.1	1,424
80	Multicentric carpotarsal osteolysis syndrome is caused by only a few domainâ€specific mutations in <i>MAFB</i> , a negative regulator of RANKLâ€induced osteoclastogenesis. American Journal of Medical Genetics, Part A, 2014, 164, 2287-2293.	0.7	36
81	Rapid Skeletal Turnover in a Radiographic Mimic of Osteopetrosis. Journal of Bone and Mineral Research, 2014, 29, 2601-2609.	3.1	12
82	Panostotic Expansile Bone Disease With Massive Jaw Tumor Formation and a Novel Mutation in the Signal Peptide of RANK. Journal of Bone and Mineral Research, 2014, 29, 911-921.	3.1	18
83	Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy. Journal of Bone and Mineral Research, 2013, 28, 419-430.	3.1	74
84	Acute Severe Hypercalcemia After Traumatic Fractures and Immobilization in Hypophosphatasia Complicated by Chronic Renal Failure. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4606-4612.	1.8	24
85	Outcome of Perinatal Hypophosphatasia in Manitoba Mennonites: A Retrospective Cohort Analysis. JIMD Reports, 2013, 11, 73-78.	0.7	52
86	Juvenile Paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous <i>TNFRSF11B</i> mutation. Journal of Bone and Mineral Research, 2013, 28, 1501-1508.	3.1	26
87	Hypophosphatasia. , 2013, , 337-360.		26
88	Mendelian Disorders of RANKL/OPG/RANK Signaling. , 2013, , 309-324.		6
89	Pregnancy-Associated Osteoporosis With a Heterozygous Deactivating LDL Receptor-Related Protein 5 (<i>LRP5</i>) Mutation and a Homozygous Methylenetetrahydrofolate Reductase (<i>MTHFR</i>) Polymorphism. Journal of Bone and Mineral Research, 2013, 29, 922-928.	3.1	24
90	Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia. New England Journal of Medicine, 2012, 366, 904-913.	13.9	463

۶

#	Article	IF	CITATIONS
91	Dual-Energy X-Ray Absorptiometry Interpretation: A Simple Equation for Height Correction in Preteenage Children. Journal of Clinical Densitometry, 2012, 15, 267-274.	0.5	15
92	Whole-exome sequencing identifies mutations in the nucleoside transporter gene SLC29A3 in dysosteosclerosis, a form of osteopetrosis. Human Molecular Genetics, 2012, 21, 4904-4909.	1.4	81
93	Hypophosphatasia. , 2012, , 771-794.		22
94	Fibrodysplasia ossificans progressiva: Middle-age onset of heterotopic ossification from a unique missense mutation (c.974G > C, p.G325A) in <i>ACVR1</i> . Journal of Bone and Mineral Resear 2012, 27, 729-737.	ch3.1	47
95	"Atypical femoral fractures―during bisphosphonate exposure in adult hypophosphatasia. Journal of Bone and Mineral Research, 2012, 27, 987-994.	3.1	159
96	Enzyme replacement prevents enamel defects in hypophosphatasia mice. Journal of Bone and Mineral Research, 2012, 27, 1722-1734.	3.1	74
97	Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. Bone, 2011, 49, 250-256.	1.4	44
98	COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. Human Mutation, 2011, 32, 598-609.	1.1	119
99	Camurati-engelmann disease: Unique variant featuring a novel mutation in <i>TGFβ1</i> encoding transforming growth factor beta 1 and a missense change in <i>TNFSF11</i> encoding RANK ligand. Journal of Bone and Mineral Research, 2011, 26, 920-933.	3.1	39
100	Hypophosphatasia: Nonlethal disease despite skeletal presentation in utero (17 new cases and) Tj ETQq0 0 0 rgE	T /Overlov 3.1	ck 10 Tf 50 3 123
101	Skeletal Fluorosis from Brewed Tea. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2318-2324.	1.8	44
102	Approach to the Patient with Metabolic Bone Disease. , 2011, , 807-822.		1
103	Buschke-Ollendorff Syndrome. Archives of Dermatology, 2010, 146, 63-8.	1.7	30
104	Polycystic Bone Disease. Journal of Bone and Mineral Research, 2010, 15, 373-373.	3.1	1
105	Elevated serum lactate dehydrogenase isoenzymes and aspartate transaminase distinguish Albers-Schönberg disease (Chloride Channel 7 Deficiency Osteopetrosis) among the sclerosing bone disorders. Journal of Bone and Mineral Research, 2010, 25, 2515-2526.	3.1	38
106	Dysosteosclerosis presents as an "Osteoclast-Poor―form of osteopetrosis: Comprehensive investigation of a 3-year-old girl and literature review. Journal of Bone and Mineral Research, 2010, 25, 2527-2539.	3.1	36
107	Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research. Journal of Bone and Mineral Research, 2010, 25, 2267-2294.	3.1	994
108	Physiological role of alkaline phosphatase explored in hypophosphatasia. Annals of the New York Academy of Sciences, 2010, 1192, 190-200.	1.8	294

ARTICLE IF CITATIONS 2009 Santa Fe Bone Symposium. Journal of Clinical Densitometry, 2010, 13, 1-9. Hereditary Disorders of the Skeleton., 2010, , 1250-1260. 110 0 Atypical Femoral Fractures, Bisphosphonates, and Adult Hypophosphatasia. Journal of Bone and 111 3.1 124 Mineral Research, 2009, 24, 1132-1134. Chronic Recurrent Multifocal Osteomyelitis Mimicked in Childhood Hypophosphatasia. Journal of 112 3.1 61 Bone and Mineral Research, 2009, 24, 1493-1505. Enzyme Replacement Therapy for Murine Hypophosphatasia. Journal of Bone and Mineral Research, 3.1 222 2008, 23, 777-787. 114 Skeletal Fluorosis From Instant Tea. Journal of Bone and Mineral Research, 2008, 23, 759-769. 3.1 43 Bisphosphonate-Induced Osteopetrosis: Novel Bone Modeling Defects, Metaphyseal Osteopenia, and Osteosclerosis Fractures After Drug Exposure Ceases. Journal of Bone and Mineral Research, 2008, 23, 3.1 88 1698-1707. Autosomal Recessive Hypophosphatasia Manifesting <i>in Utero</i>ivith Long Bone Deformity but Showing Spontaneous Postnatal Improvement. Journal of Clinical Endocrinology and Metabolism, 116 1.8 28 2008, 93, 3443-3448. Hypophosphatasia., 2008, , 1573-1598. Infantile Hypophosphatasia: Transplantation Therapy Trial Using Bone Fragments and Cultured 118 1.8 108 Osteoblasts. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2923-2930. Sporadic Hyperphosphatasia Syndrome Featuring Periostitis and Accelerated Skeletal Turnover without Receptor Activator of Nuclear Factor-1ºB, Osteoprotegerin, or Sequestosome-1 Gene Defects. 119 1.8 Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1897-1901. Adult Hypophosphatasia Treated with Teriparatide. Journal of Clinical Endocrinology and Metabolism, 120 1.8 149 2007, 92, 1203-1208. Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone, 2007, 40, 1655-1661. 1.4 141 Juvenile Paget's Disease: The Second Reported, Oldest Patient Is Homozygous for the TNFRSF11B "Balkan〕Mutation (966_969delTGACinsCTT), Which Elevates Circúlating Immunoreactive 122 3.136 Osteoprotegerin Levels. Journal of Bone and Mineral Research, 2007, 22, 938-946. Recovery From Skeletal Fluorosis. Journal of Bone and Mineral Research, 2007, 22, 1476-1476. 3.1 Paget's Disease of Bone. New England Journal of Medicine, 2006, 355, 593-600. 124 13.9 126 Fluoride Levels in Bottled Teas. American Journal of Medicine, 2006, 119, 189-190. 0.6 Homozygosity for TNSALP mutation 1348c>T (Arg433Cys) causes infantile hypophosphatasia manifesting 126 transient disease correction and variably lethal outcome in a kindred of black ancestry. Journal of 0.9 36

MICHAEL P WHYTE

Pediatrics, 2006, 148, 753-758.

#	Article	IF	CITATIONS
127	Low Serum Alkaline Phosphatase Activity and Pathologic Fracture: Case Report and Brief Review of Hypophosphatasia Diagnosed in Adulthood. Endocrine Practice, 2006, 12, 676-681.	1.1	56
128	Paget's Disease of Bone and Genetic Disorders of RANKL/OPG/RANK/NF-ÂB Signaling. Annals of the New York Academy of Sciences, 2006, 1068, 143-164.	1.8	84
129	Recovery From Skeletal Fluorosis (an Enigmatic, American Case). Journal of Bone and Mineral Research, 2006, 22, 163-170.	3.1	52
130	Deactivating Germline Mutations in LEMD3 Cause Osteopoikilosis and Buschke-Ollendorff Syndrome, but Not Sporadic Melorheostosis. Journal of Bone and Mineral Research, 2006, 22, 243-250.	3.1	74
131	Manifestations in a family with autosomal dominant bone fragility and limb-girdle myopathy. American Journal of Medical Genetics, Part A, 2006, 140A, 322-330.	0.7	9
132	Rare Bone Diseases. , 2006, , 811-829.		0
133	Skeletal changes in epidermal nevus syndrome: Does focal bone disease harbor clues concerning pathogenesis?. American Journal of Medical Genetics, Part A, 2005, 139A, 67-77.	0.7	42
134	Misinterpretation of Osteodensitometry With High Bone Density. Journal of Clinical Densitometry, 2005, 8, 1-6.	0.5	43
135	Skeletal fluorosis and instant tea. American Journal of Medicine, 2005, 118, 78-82.	0.6	73
136	High Bone Mass. , 2005, , 147-150.		1
137	High-Bone-Mass Disease andLRP5. New England Journal of Medicine, 2004, 350, 2096-2099.	13.9	63
137 138	High-Bone-Mass Disease andLRP5. New England Journal of Medicine, 2004, 350, 2096-2099. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics, 2004, 36, 377-381.	13.9 9.4	63 1,257
	Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused		
138	Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics, 2004, 36, 377-381. Oropharyngeal Skeletal Disease Accompanying High Bone Mass and Novel LRP5 Mutation. Journal of	9.4	1,257
138 139	Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics, 2004, 36, 377-381. Oropharyngeal Skeletal Disease Accompanying High Bone Mass and Novel LRP5 Mutation. Journal of Bone and Mineral Research, 2004, 20, 878-885. Heritable disorders of the RANKL/OPG/RANK signaling pathway. Journal of Musculoskeletal Neuronal	9.4 3.1	1,257 57
138 139 140	Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics, 2004, 36, 377-381. Oropharyngeal Skeletal Disease Accompanying High Bone Mass and Novel LRP5 Mutation. Journal of Bone and Mineral Research, 2004, 20, 878-885. Heritable disorders of the RANKL/OPG/RANK signaling pathway. Journal of Musculoskeletal Neuronal Interactions, 2004, 4, 254-67. Marrow Cell Transplantation for Infantile Hypophosphatasia. Journal of Bone and Mineral Research,	9.4 3.1 0.1	1,257 57 37
138 139 140 141	Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics, 2004, 36, 377-381. Oropharyngeal Skeletal Disease Accompanying High Bone Mass and Novel LRP5 Mutation. Journal of Bone and Mineral Research, 2004, 20, 878-885. Heritable disorders of the RANKL/OPC/RANK signaling pathway. Journal of Musculoskeletal Neuronal Interactions, 2004, 4, 254-67. Marrow Cell Transplantation for Infantile Hypophosphatasia. Journal of Bone and Mineral Research, 2003, 18, 624-636.	9.4 3.1 0.1 3.1	1,257 57 37 155

6

#	Article	IF	CITATIONS
145	Familial Expansile Osteolysis (Excessive RANK Effect) in a 5-Generation American Kindred. Medicine (United States), 2002, 81, 101-121.	0.4	39
146	Denaturing Gradient Gel Electrophoresis Analysis of the Tissue Nonspecific Alkaline Phosphatase Isoenzyme Gene in Hypophosphatasia. Molecular Genetics and Metabolism, 2002, 75, 143-153.	0.5	66
147	Elevated plasma 4-pyridoxic acid in renal insufficiency. American Journal of Clinical Nutrition, 2002, 75, 57-64.	2.2	33
148	Expansile Skeletal Hyperphosphatasia Is Caused by a 15-Base Pair Tandem Duplication in TNFRSF11A Encoding RANK and Is Allelic to Familial Expansile Osteolysis. Journal of Bone and Mineral Research, 2002, 17, 26-29.	3.1	163
149	Clinical Delineation and Localization to Chromosome 9p13.3–p12 of a Unique Dominant Disorder in Four Families: Hereditary Inclusion Body Myopathy, Paget Disease of Bone, and Frontotemporal Dementia. Molecular Genetics and Metabolism, 2001, 74, 458-475.	0.5	191
150	Preonset Studies of Spondyloepiphyseal Dysplasia Tarda Caused by a Novel 2-Base Pair Deletion in SEDL Encoding Sedlin*. Journal of Bone and Mineral Research, 2001, 16, 2245-2250.	3.1	7
151	Pseudo-(Tumor-Induced) Rickets. Journal of Bone and Mineral Research, 2001, 16, 1564-1571.	3.1	11
152	Historical Vignette: Hypophosphatasia: Molecular Diagnosis of Rathbun's Original Case. Journal of Bone and Mineral Research, 2001, 16, 1724-1727.	3.1	33
153	X-Linked Hypophosphatemia Attributable to Pseudoexons of the PHEX Gene. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3840-3844.	1.8	10
154	Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nature Genetics, 2000, 24, 45-48.	9.4	457
155	Deficiency of the α-Subunit of the Stimulatory G Protein and Severe Extraskeletal Ossification. Journal of Bone and Mineral Research, 2000, 15, 2074-2083.	3.1	110
156	Expansile Skeletal Hyperphosphatasia: A New Familial Metabolic Bone Disease. Journal of Bone and Mineral Research, 2000, 15, 2330-2344.	3.1	63
157	"Café-Au-Lait Spots―Caused by Vitiligo in McCune-Albright Syndrome. Journal of Bone and Mineral Research, 2000, 15, 2521-2523.	3.1	0
158	Alkaline Phosphatase Knock-Out Mice Recapitulate the Metabolic and Skeletal Defects of Infantile Hypophosphatasia. Journal of Bone and Mineral Research, 1999, 14, 2015-2026.	3.1	343
159	Polycystic Bone Disease: A New, Autosomal Dominant Disorder. Journal of Bone and Mineral Research, 1999, 14, 1261-1271.	3.1	6
160	Mild autosomal dominant hypophosphatasia: In utero presentation in two families. , 1999, 86, 410-415.		61
161	Mild hypophosphatasia mimicking severe osteogenesis imperfecta in utero: Bent but not broken. , 1999, 86, 434-438.		70

Bilateral radial ray hypoplasia with multiple epiphyseal dysplasia. , 1998, 77, 182-187.

#	Article	IF	CITATIONS
163	Skeletal Disorders Characterized By Osteosclerosis Or Hyperostosis. , 1998, , 697-739e.		11
164	Calcinosis Universalis Complicating Juvenile Dermatomyositis: Resolution During Probenecid Therapy1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3536-3542.	1.8	52
165	Extraskeletal Osteoclastomas Responsive to Dexamethasone Treatment in Paget Bone Disease1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3826-3834.	1.8	17
166	Paget Bone Disease Involving Young Adults in 3 Generations of a Korean Family. Medicine (United) Tj ETQq0 0 (OrgBT ∕Ov 0.4	erlock 10 Tf 5 28
167	Searching for Gene Defects That Cause High Bone Mass. American Journal of Human Genetics, 1997, 60, 1309-1311.	2.6	29
168	Linkage Studies of a Missouri Kindred with Autosomal Dominant Spondyloepimetaphyseal Dysplasia (SEMD) Indicate Genetic Heterogeneity. Journal of Bone and Mineral Research, 1997, 12, 1204-1209.	3.1	10
169	Surgical management of calcinosis cutis universalis in systemic lupus erythematosus. Arthritis and Rheumatism, 1997, 40, 570-572.	6.7	37
170	Juvenile paget disease: Life-long features of a mildly affected young woman. Journal of Bone and Mineral Research, 1996, 11, 132-142.	3.1	46
171	Doubling skeletal mass during adult life: The syndrome of diffuse osteosclerosis after intravenous drug abuse. Journal of Bone and Mineral Research, 1996, 11, 554-558.	3.1	37
172	Absence of paramyxo virus transcripts in juvenile paget bone disease. Journal of Bone and Mineral Research, 1996, 11, 1041-1041.	3.1	6
173	Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders. Journal of Bone and Mineral Research, 1996, 11, 1438-1443.	3.1	54
174	Linkage studies in a kindred from Oklahoma, with familial benign (hypocalciuric) hypercalcaemia (FBH) and developmental elevations in serum parathyroid hormone levels, indicate a third locus for FBH. Human Genetics, 1995, 96, 183-187.	1.8	61
175	Infantile hypophosphatasia: Successful prenatal assessment by testing for tissue-non-specific alkaline phosphatase isoenzyme gene mutations. Prenatal Diagnosis, 1995, 15, 1001-1006.	1.1	50
176	Hypophosphatasia and the Role of Alkaline Phosphatase in Skeletal Mineralization*. Endocrine Reviews, 1994, 15, 439-461.	8.9	425
177	Mutation analysis of coding sequences for type I procollagen in individuals with low bone density. Journal of Bone and Mineral Research, 1994, 9, 923-932.	3.1	94
178	Evidence against a role for alkaline phosphatase in the dephosphorylation of plasma membrane proteins: Hypophosphatasia fibroblast study. Journal of Cellular Biochemistry, 1993, 53, 43-50.	1.2	18
179	Painful diffuse osteosclerosis after intravenous drug abuse. American Journal of Medicine, 1992, 93, 371-381.	0.6	45
180	X-linked hypophosphatemic rickets: A study (with literature review) of linear growth response to calcitriol and phosphate therapy. Journal of Bone and Mineral Research, 1992, 7, 583-597.	3.1	82

#	Article	IF	CITATIONS
181	Hypercalciuria in children severely affected with osteogenesis imperfecta. Journal of Pediatrics, 1991, 119, 51-57.	0.9	49
182	X-linked hypophosphatemia: skeletal mass in adults assessed by histomorphometry, computed tomography, and absorptiometry. American Journal of Medicine, 1991, 90, 63-69.	0.6	69
183	Hypophosphatasia and the Extracellular Metabolism of Inorganic Pyrophosphate: Clinical and Laboratory Aspects: Part I. Critical Reviews in Clinical Laboratory Sciences, 1991, 28, 175-194.	2.7	98
184	Normal left ventricular performance in children with x-linked hypophosphatemic rickets: A doppler echocardiography study. Journal of Bone and Mineral Research, 1990, 5, 469-474.	3.1	32
185	Infantile hypophosphatasia: Autosomal recessive transmission to two related sibships. American Journal of Medical Genetics Part A, 1990, 36, 15-22.	2.4	42
186	Hypotrichosis with spondyloepimetaphyseal dysplasia in three generations: A new autosomal dominant syndrome. American Journal of Medical Genetics Part A, 1990, 36, 288-291.	2.4	15
187	First Identification of a Gene Defect for Hypophosphatasia: Evidence That Alkaline Phosphatase Acts in Skeletal Mineralization. Connective Tissue Research, 1989, 21, 99-106.	1.1	25
188	X-Linked Hypophosphatemia. Medicine (United States), 1989, 68, 336-352.	0.4	125
189	Central osteosclerosis with ectodermal dysplasia: Clinical, laboratory, radiologic, and histopathologic characterization with review of the literature. Journal of Bone and Mineral Research, 1989, 4, 863-875.	3.1	17
190	Alkaline phosphatase is an ectoenzyme that acts on micromolar concentrations of natural substrates at physiologic pH in human osteosarcoma (SAOS-2) cells. Archives of Biochemistry and Biophysics, 1988, 264, 400-409.	1.4	95
191	Infantile hypophosphatasia: Enzymatic defect explored with alkaline phosphatase-deficient skin fibroblasts in culture. Calcified Tissue International, 1987, 40, 244-252.	1.5	26
192	Infantile hypophosphatasia fibroblasts proliferate normally in culture: Evidence against a role for alkaline phosphatase (tissue nonspecific isoenzyme) in the regulation of cell growth and differentiation. Calcified Tissue International, 1987, 40, 1-7.	1.5	26
193	Infantile hypophosphatasia: Normalization of circulating bone alkaline phosphatase activity followed by skeletal remineralization. Journal of Pediatrics, 1986, 108, 82-88.	0.9	57
194	Normal Activity of Nucleoside Triphosphate Pyrophosphatase in Alkaline Phosphatase-Deficient Fibroblasts from Patients with Infantile Hypophosphatasia*. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 1237-1241.	1.8	23
195	Macroepiphyseal dysplasia with symptomatic osteoporosis, wrinkled skin, and aged appearance: A presumed autosomal recessive condition. Skeletal Radiology, 1986, 15, 47-51.	1.2	7
196	Carbonic Anhydrase II Deficiency in 12 Families with the Autosomal Recessive Syndrome of Osteopetrosis with Renal Tubular Acidosis and Cerebral Calcification. New England Journal of Medicine, 1985, 313, 139-145.	13.9	298
197	Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: Results in three additional patients. Journal of Pediatrics, 1984, 105, 926-933.	0.9	90
198	Hypophosphatasia. Medicine (United States), 1984, 63, 12-24.	0.4	115

#	Article	IF	CITATIONS
199	Alkaline Phosphatase Deficiency in Cultured Skin Fibroblasts from Patients with Hypophosphatasia: Comparison of the Infantile, Childhood, and Adult Forms*. Journal of Clinical Endocrinology and Metabolism, 1983, 57, 831-837.	1.8	33
200	Circulating Vitamin D Metabolite Levels in Hypophosphatasia*. Journal of Clinical Endocrinology and Metabolism, 1982, 55, 178-180.	1.8	28
201	Infantile hypophosphatasia: Enzyme replacement therapy by intravenous infusion of alkaline phosphatase-rich plasma from patients with Paget bone disease. Journal of Pediatrics, 1982, 101, 379-386.	0.9	77
202	Adult hypophosphatasia with chondrocalcinosis and arthropathy. American Journal of Medicine, 1982, 72, 631-641.	0.6	97
203	Postmenopausal osteoporosis. American Journal of Medicine, 1982, 72, 193-202.	0.6	185
204	Mixed-sclerosing-bone-dystrophy: Report of a case and review of the literature. Skeletal Radiology, 1981, 6, 95-102.	1.2	48
205	Biochemical and Ultrastructural Demonstration of Elastin Accumulation in the Skin Lesions of the Buschke-Ollendorff Syndrome. Journal of Investigative Dermatology, 1981, 76, 284-287.	0.3	71
206	Osteopetrosis, renal tubular acidosis and basal ganglia calcification in three sisters. American Journal of Medicine, 1980, 69, 64-74.	0.6	109
207	Adult Hypophosphatasia. Medicine (United States), 1979, 58, 329-347.	0.4	118
208	Idiopathic Multicentric Osteolysis. Arthritis and Rheumatism, 1978, 21, 367-376.	6.7	27
209	Heritable Forms of Rickets and Osteomalacia. , 0, , 765-787.		6
210	Hypophosphatasia: a retrospective natural history study of the severe perinatal and infantile forms. Bone Abstracts, 0, , .	0.0	6